|
Name of the drug | Class | Mechanism of action | Important GP organisms covered | Dose and Route† | Phase of testing‡ | Serious Adverse effects |
|
Delafloxacin | Fluoro-quinolone | Inhibit DNA gyrase and Topoisomerase IV | MRSA, MSSA, St. pyogenes, E. faecalis | 300 mg IV/ 450 mg oral | USFDA approved in June 2017 | Tendinitis and tendon rupture, peripheral neuropathy, Central nervous system effects |
Nemonoxacin | MRSA, VRSA | 250-750 mg, oral, IV | Phase III | None reported |
Levonadifloxacin | MRSA, VRSA | 1000 mg oral, 800 mg IV | Phase III | None reported |
Alalevonadifloxacin | MRSA, VRSA | 1000 mg oral | Phase III | None reported |
|
Solithromycin | Fluoro-ketolide | Inhibits protein synthesis by binding to 50s ribosome subunit and blocking peptide chain elongation | S. aureus, St. pneumoniae | 800 mg oral | Phase III | Possible hepatotoxicity |
|
Omadacycline | Tetracycline | Inhibits protein synthesis by binding to 30s ribosome subunit and blocking binding of aminoacid-tRNA with mRNA | S. aureus (MSSA), St. pneumoniae | 100-200 mg IV; 300-450 mg oral | USFDA approved in October 2018 | Similar to other tetracyclines |
Eravacycline | E faecalis, E faecium, S. Aureus, St anginosus group | 1 mg/kg IV infusion | USFDA approved in August 2018 | Similar to other tetracyclines |
|
Tedizolid | Oxazolidinone | Inhibits protein synthesis by binding to the 50S ribosome subunit | MRSA, MSSA, St. pyogenes, St. agalactiae, S. anginosus, E. faecalis | 200 mg oral or IV infusion | USFDA approved in June 2014 | Similar to linezolid |
|
Lanopepden (GSK’322) | Peptidyl deformylase inhibitor | Inhibits bacterial protein synthesis | St. pneumoniae, St. pyogenes, S. aureus | 1500 mg oral | Phase II | None reported |
|
AFN-1252 | Fabl (enoyl ACP reductase) inhibitor | Interferes with essential bacterial fatty acid biosynthetic pathway | S. aureus, S. epidermidis, other staphylococci | 200 mg oral | Phase II | None reported |
|